Integra Lifesciences Holdings Corp (IART) · Oct 21, 2026 · Earnings
In line — Adjusted EPS $0.59 vs ~$0.56 consensus; revenue $411.2M vs ~$413.2M
Integra’s Q3 earnings landed near expectations: adjusted EPS beat modestly, but revenue, Tissue Reconstruction, and gross margin disappointed.
Integra is trying to restore growth in its tissue-reconstruction franchise while shifting manufacturing to Braintree and recovering from the Cincinnati flood; Neurosurgery is currently the healthier growth engine. The October 2 preliminary update had already disclosed the flood-related revenue hit, lowered 2026 guidance, and expected recovery timing, so much of the narrative was known before this release.
The quarter was broadly in line, not a clean beat. Revenue of $411.2 million rose 2.3% reported and 2.5% organically, slightly below the published consensus of about $413.2 million, while adjusted EPS of $0.59 exceeded the roughly $0.56 expectation. The result also landed at the top of the company’s already disclosed preliminary EPS range, making the earnings upside incremental rather than a fresh surprise.
| Metric | Q3 2026 | Q3 2025 / expectation | Read |
|---|---|---|---|
| Revenue | $411.2M | $402.1M prior year; ~$413.2M consensus | Slightly below consensus |
| Organic revenue growth | 2.5% | 0% prior-year comparison base | Positive but modest |
| Adjusted EPS | $0.59 | $0.54 prior year; ~$0.56 consensus | Modest beat |
| Adjusted EBITDA | $79.8M | $78.5M | Essentially flat |
| Adjusted gross margin | 61.1% | 62.9% | Down 180 bps |
| Net debt | $1.52B | $1.60B at Dec. 31, 2025 | Lower leverage |
| Free cash flow | $85.7M | $25.8M | Meaningful improvement |
Neurosurgery is carrying the operating story. Specialty Surgical revenue grew 3.9%, led by 6.2% Neurosurgery growth, but Tissue Reconstruction declined 2.2%, with Wound Reconstruction Solutions down 2.9%. That mix matters because management explicitly lowered its outlook for parts of Tissue Reconstruction while keeping Specialty Surgery assumptions unchanged.
Margins remain the weak spot beneath the adjusted earnings beat. Adjusted gross margin fell to 61.1% from 62.9%, despite lower structural-optimization, EU regulatory, and Braintree-transition charges. The company still had to absorb $7 million of flood-related revenue disruption and added Cincinnati costs, so the adjusted EPS improvement was helped by lower special charges and favorable other income rather than broad-based operating expansion.
Cash generation and financing flexibility improved, but debt remains central to the story. Nine-month operating cash flow rose to $128.6 million from $38.6 million, and net debt declined to $1.52 billion from $1.60 billion at year-end. The completed $2.1 billion refinancing extends maturities and temporarily increases covenant capacity, but it also includes 9.5% senior notes and incremental interest expense, so the balance-sheet repair is helpful without eliminating financial pressure.
The outlook is confirmed, not improved. Fourth-quarter revenue guidance implies a decline of 0.5% to 5.2%, and full-year adjusted EPS remains $2.30 to $2.40; both ranges repeat the October 2 update rather than restore the earlier outlook. 〔0〕
Bottom line: This is a mixed, largely pre-announced quarter: adjusted EPS held up and cash flow improved, but revenue missed slightly, Tissue Reconstruction weakened, and margins compressed. The filing confirms stabilization rather than a clear return to durable growth, with Cincinnati recovery and tissue demand still doing most of the work ahead.್
Cincinnati manufacturing recovery, expected during Q2 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!